Comparison of the Effectiveness and Safety of Intense Pulsed Light (IPL) and Placebo Versus Intense Pulsed Light and Eflornithine in Idiopathic Facial Hirsutism
Keywords:Eflornithine, Intense pulsed light, Hirsutism.
AbstractBackground: Hirsutism is a distressing condition among women and one of the major causes of depression. Objective: To compare the effectiveness and safety of Eflornithine and Intense Pulsed Light versus Intense pulsed light and Placebo in idiopathic facial hirsutism. Methods: In this randomized placebo-controlled trial, 40 female patients of >18 years, suffering from idiopathic facial hirsutism with Fitzpatrick skin type III and IV, were included. Two groups, A and B were made. A-Group (right side of all patients) was treated with Intense Pulsed Light (IPL) and placebo and Group B (left side of all patients) with Intense Pulsed Light (IPL) and Eflornithine. Six sessions (each with 4-week interval) were done for both treatment modalities. Before first session and 4 weeks after the last session photographs were taken and hair count and hair reduction were calculated. Results: In Group A (Intense Pulsed Light (IPL) and Placebo) treated sites effectiveness of treatment was seen in 22 (55%) while in Group B (Intense Pulsed Light (IPL) and Eflornithine) treated sites effectiveness was seen in 35 (87.5%). This proved that efficacy of Group B treatment was higher than Group A (p-value=0.001). Earlier side effects like mild transient erythema, transient swelling and transient pain were seen with Intense Pulsed Light (IPL) in 100% of the patients and late side effects in both groups like folliculitis (p-value=0.692) and hyperpigmentation (p-value=0.064) were also recorded and compared. Conclusion: Intense Pulsed Light (IPL) and Eflornithine combination is more successful than Intense Pulsed Light (IPL) and Placebo for the treatment of idiopathic facial hirsutism. Both treatments were equally safe.
How to Cite
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments email@example.com